Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Deals

Rendu Biotechnology Partners with Green Apple Medical System for RNA Diagnostics Expansion

Fineline Cube Feb 20, 2025

Rendu Biotechnology Co., Ltd., (SHA: 688193) a Shanghai-based specialist in RNA molecular diagnostics, has entered...

Company Deals

Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline

Fineline Cube Feb 20, 2025

China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...

Company Legal / IP

AstraZeneca Faces Class Action Lawsuits Over China Legal Issues

Fineline Cube Feb 20, 2025

AstraZeneca plc (AZ, NASDAQ: AZN) is facing multiple class action lawsuits in the United States...

Company Deals Drug

Biogen Licenses Stoke Therapeutics’ Zorevunersen for Dravet Syndrome Outside Americas

Fineline Cube Feb 19, 2025

US-based Biogen Inc. (NASDAQ: BIIB) has entered into a licensing agreement with Stoke Therapeutics, Inc....

Company Drug

TAHO Pharma’s TAH3311 Oral Film Shows Bioequivalence to Eliquis in Study

Fineline Cube Feb 19, 2025

Taiwan-based TAHO Pharmaceuticals announced positive preliminary results from a pivotal study for its TAH3311 oral...

Company Drug

Sanofi’s Dupixent Receives Priority Review from FDA for Bullous Pemphigoid Treatment

Fineline Cube Feb 19, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) announced that the US Food and Drug Administration (FDA) has...

Company Deals

CSPC Pharma Licenses SYS 6005 to Radiance Biopharma for Global Markets

Fineline Cube Feb 19, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced a licensing agreement with Radiance Biopharma, Inc.,...

Company Drug

Biokin Pharmaceutical’s BL-M07D1 Receives NMPA Approval for Phase II/III Study in HER2+ Breast Cancer

Fineline Cube Feb 19, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced that it has received approval from...

Company Drug

Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review

Fineline Cube Feb 19, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...

Company Drug

Merck’s Welireg Wins Conditional EU Approval for VHL Disease and Advanced RCC

Fineline Cube Feb 19, 2025

US pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) announced that it has received...

Company

GSK and Abbott Announce Leadership Changes in Key Roles

Fineline Cube Feb 19, 2025

Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON:...

Company

Medtronic Q3 Earnings Show 4.1% Organic Growth, Driven by Cardiac Ablation

Fineline Cube Feb 19, 2025

US-Irish medical device company Medtronic (NYSE: MDT) reported financial results for the third quarter (Q3)...

Company Deals

QuantumPharm and Hengjian Launch GBA AI+ Innovation Consortium

Fineline Cube Feb 19, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., and Guangdong Hengjian Investment Holding...

Company

Deepwise Information Integrates DeepSeek into Medical Data Platform

Fineline Cube Feb 19, 2025

Deepwise Information, a leading artificial intelligence company in the medical field, has fully integrated its...

Company

Weimai Qingtong Medical Technology Completes Tens of Millions Yuan B+ Round

Fineline Cube Feb 19, 2025

Weimai Qingtong Medical Technology (WEMT), a medical device company based in Wuxi, has completed a...

Company Drug

InnoCare Pharma Receives NMPA Approval for Mesutoclax Phase III Study in CLL/SLL

Fineline Cube Feb 18, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received approval from...

Company Drug

Hengrui Pharma’s HR19034 Eye Drops for Myopia Delay Accepted by NMPA

Fineline Cube Feb 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its market filing for HR19034 eye...

Company Drug

Gan & Lee Pharmaceuticals Doses First Patient in GZR4 Phase III Study for Diabetes

Fineline Cube Feb 18, 2025

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...

Company Deals

Stedical Scientific Raises RMB100M in Series B Financing for Global Expansion

Fineline Cube Feb 18, 2025

Stedical Scientific, a Hangzhou-based tissue engineering and regenerative medicine company, has raised over RMB100 million...

Company Drug

Zelgen Biopharmaceuticals’ ZG005 Bispecific Antibody Receives NMPA Approval for Biliary Tract Cancer Trials

Fineline Cube Feb 18, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received clinical trial...

Posts pagination

1 … 245 246 247 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.